Recursion has initiated the EXCELERIZE Phase 1 clinical trial of REC-3565, a selective MALT1 inhibitor designed to treat relapsed or refractory B-cell lymphomas.
Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.
Recursion's REC-3565, a MALT1 inhibitor for B-cell malignancies, has been cleared for a Phase 1 clinical trial by the UK MHRA, addressing unmet needs in hematologic cancers.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.